Navigation Links
Schizophrenics On Medication At An Increased Risk For Developing Diabetes

A recent study shows , schizophrenics treated with clozapine and olanzapine may be at an increased risk for developing type 2 diabetes. Patients taking these antipsychotic agents resisted insulin // and had impairment of glucose effectiveness compared with patients taking another drug under study.

Researchers evaluated 36 non-obese people with schizophrenia or schizoaffective disorder who were treated with clozapine (Clozaril), olanzapine (Zyprexa, Zydis), or risperidone (Risperdal). The participants followed a certain diet to maintain body weight and fasted before having a glucose tolerance test. Schizophrenics were found to have a much shorter life expectancy than the general population attributable to many factors, including cardiovascular disease.

Thus researchers conclude, that psychiatrists and primary care professionals should be aware that patients treated with clozapine and olanzapine may be at increased risk for insulin resistance, even if not obese and patients treated with these agents should be routinely screened and counseled to reduce risk, and provided early interventions.
'"/>




Page: 1

Related medicine news :

1. Music therapy for Schizophrenics
2. Schizophrenics At Greater Risk Of Developing Chronic Diseases
3. Sway Schizophrenics With Incentives to Avail Regular Treatment
4. What happens when Medications go wrong?
5. Medications to Prevent Relapse to Cocaine Use
6. More Elderly Take Inappropriate and Harmful Medications
7. Medications for depression
8. Medications linked to xerostomia and caries
9. Medication recuperates fat distribution in diabetes
10. Pharmacist’s Role in Medication Error
11. The Downside of Asthma Medication
Post Your Comments:
(Date:7/18/2008)...d Mexican Cuisine are Featured at East LA Meets Na... Services Corporation, LOS ANGELES, July 18 /PRNe...d annual East LA Meets Napa celebration featuring ... wine makers and 20 Los Angeles area Mexican,resta...wine and culinary,enthusiasts who enjoyed great mu...
(Date:7/18/2008)...on the wagon an antidepressant restored brain,s ab... 18 (HealthDay News) -- Giving up your few drinks ...ion, a new study says. , "Our research in an an...nence from alcohol drinking and depression," study...hiatry and pharmacology in the University of North...
(Date:7/18/2008)...t weight loss yields significant health benefits, ...lition -- a group of,experts on overweight and obe...a to reevaluate the way they report on weight loss... news coverage and editorial content that,leads co...ieters if they,lose an enormous amount of weight, ...
(Date:7/18/2008)...Is Not What America Signed Up For, WASHINGTON, Ju...cCain,s,top economic advisor, Phil Gramm, echoed M...were "psychological" by saying Americans are in a ...nation of whiners." While McCain,distanced himself...d as,McCain,s top economic adviser. Now, John McCa...
Breaking Medicine News(10 mins):Health News:Move Over Margarita! Mexican Food has a New Dinner Partner 2Health News:Move Over Margarita! Mexican Food has a New Dinner Partner 3Health News:Research Finds Causal Link Between Ending Drinking, Depression 2Health News:Medical Experts Call on Media to Rethink Coverage of Weight Loss 2Health News:Medical Experts Call on Media to Rethink Coverage of Weight Loss 3Health News:DNC: McCain Watch: The Economy 2Health News:DNC: McCain Watch: The Economy 3
...us University Hospital, Denmark, in a first of its...with a group of ankle injury patients. They found ... in the neck, head, shoulder, arm and even lower b...y of the two groups, pain in the ankle injury grou...
... toenails is a problem that occurs in 1 in 2 perso...y a long standing fungal infection and it gives to...tors at the Mayo Clinic advice consulting with a c...ug. However, these drugs might cause some side eff...
...s Chairman, Tajendra Khanna, in a recent seminar o...ity on 'Managing Corporate Reputation', spoke abou...rugs market. He said that their products would cre...market - Dabur, which has 60 per cent market share...
...r ectopy, another name for premature heart beat, d...searchers to be a better predictor of an increased.... Doctors from Cleveland Clinic Foundation observe...re, valve disease or arrhythmia. They were referre...
Other Medicine News:
(Date:7/16/2008)... MOUNTAIN VIEW, Calif., July 16 /PRNewswire-Fi...PP ) announced that the positive results,from a Ph...d,pharmacokinetics of MAP0004 in adult asthmatics ...l Research and Opinion. MAP Pharmaceuticals is,dev...stered therapy, as a,potential treatment for migra...
(Date:7/15/2008)... ATHENS, Ga., July 15 /- Abeome C...nced today a strategic equity,investment by Cato B...Ltd.,its global contract research and development...ll help support continued development of Abeome,s ...y technology vastly improves the development of,mo...
(Date:7/15/2008)... Proceeds to Fund Completion of Phase III Trials ...oma and Metastatic Colorectal Cancer and Phase I/I...asia Studies, BELLEVUE, Wash., July 15 /PRNewswir...tely held company developing Light Infusion Therap...ons, today announced that it,has raised $40.1 mill...
(Date:7/15/2008)... Most Up-to-Date Analysis of the Alzheimer,s Dis...rom Decision Resources, WALTHAM, Mass., July 15 /...d,s leading research and advisory firms for pharma...riad Genetics/Lundbeck,s decision to,discontinue t...to-market,disease-modifying Alzheimer,s disease tr...
Breaking Medicine Technology:MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion 2MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion 3MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion 4Abeome and Cato Research to Collaborate on Ovarian Cancer Therapeutic 2Light Sciences Oncology Raises $40.1 Million in Series C Financing 2Bapineuzumab To Become the First-to-Market Disease-Modifying Alzheimer's Drug After Flurizan's Discontinuation 2Does the victim affect snake venom composition 3F 588 1Yale scientists make 2 giant steps in advancement of quantum computing 881 1Yale scientists make 2 giant steps in advancement of quantum computing 881 2Yale scientists make 2 giant steps in advancement of quantum computing 881 3C diff infection 4 times more likely to kill patients with inflammatory bowel disease 2158 1HHS Provides Over 24131 Million In Energy Assistance 2156 1HHS Provides Over 24131 Million In Energy Assistance 2156 2
... Demonstrates Significant,Additional Improvement f...2, 2007 /PRNewswire-FirstCall/ --,Indevus Pharmace...e,Company,s Phase II EXPRESS trial for pagoclone i...ented today at the 47th annual,meeting of the New ...y National Institute for Mental Health (NIMH) and ...
... 12, 2007 - Critical,Therapeutics, Inc. (Nasdaq: C...a pivotal Phase III clinical trial of ZYFLO CR(TM)...007 issue of the,Journal of Asthma. ZYFLO CR was a...FDA) on May 30, 2007. Critical Therapeutics,toget... expects to,begin marketing ZYFLO CR in the U.S. i...
Other Medicine Technology:Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 2Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 3Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 4Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 5Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 6Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 7Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 8Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 9Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 2Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 3Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 4Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 5
A variety of surgical drapes that provide a vertical barrier to keep the C-arm isolated from the sterile surgical field during hip/femur fracture or trauma procedures. Available with pouches and with
...ll-in-one procedure drape made of 3M™ Steri-...elastic aperture, to create a sterile field during...ake draping quick and convenient by eliminating th...remity drapes with elastic apertures suitable for ...
...OCT, which includes bed side and near patient test...osed unique problems for hospitals and clinical la...sibility to decentralized areas focused on patient... the problem is the reality of controlling staffin...
The Abbott Commander is an automated, high-throughput immunoassay testing system. The Commander System consists of the Flexible Pipetting Center, the Parallel Processing Center, and the Dynamic Incub
Medicine Products: